Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Junwei Ning"'
Autor:
Hanbo Pan, Hang Chen, Wanyu Li, Yu Tian, Zhen Ge, Weicheng Kong, Zenan Gu, Ningyuan Zou, Hongda Zhu, Jiaqi Zhang, Yixing Tao, Junwei Ning, Jia Huang, Hui Yin, Ming Zhang, Chengwei Zhou, Hui Wang, Guodong Xu, Qingquan Luo
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 18 (2024)
Background: Coronavirus disease (COVID)-19 can lead to chronic lung damage and respiratory issues, potentially increasing surgical difficulty and risk for patients with non-small-cell lung cancer (NSCLC). However, the impacts of a COVID-19 history on
Externí odkaz:
https://doaj.org/article/460695500cd24e7baddf2e5617f4d53a
Autor:
Hanbo Pan, Ningyuan Zou, Yu Tian, Hongda Zhu, Jiaqi Zhang, Weiqiu Jin, Zenan Gu, Junwei Ning, Ziming Li, Weicheng Kong, Long Jiang, Jia Huang, Qingquan Luo
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundNeoadjuvant immunochemotherapy has been increasingly applied to treat non-small cell lung cancer (NSCLC). However, the comparison between robotic-assisted thoracoscopic surgery (RATS) and video-assisted thoracoscopic surgery (VATS) in the f
Externí odkaz:
https://doaj.org/article/f4cd89ecd50847e7a489f2250983f62b
Autor:
Tianxiang Chen, MD, PhD, Junwei Ning, MD, Jianfei Shen, MD, PhD, Hui Pan, MD, Linhai Fu, MD, Enwu Xu, MD, PhD, Han Wu, MD, Jia Huang, MD, PhD, Yunhai Yang, MD, PhD, Ziming Li, MD, PhD, Qingquan Luo, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100472- (2023)
Introduction: To analyze the feasibility and efficacy of sleeve lobectomy after neoadjuvant immunotherapy in multicenter patients with squamous cell lung cancer. Methods: We retrospectively identified patients who received neoadjuvant immunotherapy (
Externí odkaz:
https://doaj.org/article/e8c56e7d6e884749ae4f2a77ca071fea
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionAlthough robot-assisted thoracoscopic surgery (RATS) has been widely applied in treating non-small cell lung cancer (NSCLC), its advantages remain unclear for very old patients. The present study compared the perioperative outcomes and su
Externí odkaz:
https://doaj.org/article/1765e155a32e414ba717c3c8ba69087a
Autor:
Tianxiang Chen, Junwei Ning, Jianfei Shen, Hui Pan, Linhai Fu, Enwu Xu, Han Wu, Jia Huang, Yunhai Yang, Ziming Li, Qingquan Luo
Publikováno v:
JTO Clin Res Rep
INTRODUCTION: To analyze the feasibility and efficacy of sleeve lobectomy after neoadjuvant immunotherapy in multicenter patients with squamous cell lung cancer. METHODS: We retrospectively identified patients who received neoadjuvant immunotherapy (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5c73882203cd81dea586dd702c69023
https://europepmc.org/articles/PMC10064223/
https://europepmc.org/articles/PMC10064223/
Publikováno v:
Transl Lung Cancer Res
Neoadjuvant PD-(L)1 inhibitors may be promising for locally advanced non-small cell lung cancer (NSCLC) with potential pathological and survival benefits. But severe immune-related adverse events (irAEs) may cause fatal consequences which require ear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f349c53e46e00c2c7691a0935d9229d
https://doi.org/10.21037/tlcr-21-603
https://doi.org/10.21037/tlcr-21-603
Autor:
Yu Tian, Ziming Li, Zhengping Ding, Junwei Ning, Yunhai Yang, Qingquan Luo, Chongwu Li, Long Jiang, Wenwen Rong, Jia Huang, Shanshan Jiang, Xiaoke Chen, Yaofeng Shen
Publikováno v:
Cancer Immunology, Immunotherapy
Background The recent novel conception of neoadjuvant immunotherapy has generated interest among surgeons worldwide, especially the lack of experience involving surgical treatment for the neoadjuvant immunotherapy population. Methods Patients with no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13010cf5cd41ea00234ee3ed797c3b60
http://europepmc.org/articles/PMC7844548
http://europepmc.org/articles/PMC7844548
Autor:
Han Wu, Junwei Ning, Ziming Li, Duilio Divisi, Antonio Rossi, Alessio Cortellini, Sang-Won Um, Yusuke Okuma, Chiara Lazzari, Qingquan Luo, Tianxiang Chen
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: The role of surgery in combined modality therapy for selected stage IV oligometastatic (OM) non-small cell lung cancer (NSCLC) is still controversial. Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) sig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f554e616541948828098442fd1e3c96
https://europepmc.org/articles/PMC9073747/
https://europepmc.org/articles/PMC9073747/
Autor:
Alessio Campisi, Franco Stella, Liwei Song, Yunhai Yang, Angelo Paolo Ciarrocchi, Qingquan Luo, Tianxiang Chen, Andrea Dell’Amore, Junwei Ning, Ziming Li, Jia Huang
Background Stage III non-small cell lung cancer (NSCLC) encompasses a variety of local invasion and nodal involvement and its management is still under debate. Immune checkpoint inhibitors (ICIs) have been shown to improve the survival in metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45979fe278753dec3352e82bd24cf739
http://hdl.handle.net/11585/871537
http://hdl.handle.net/11585/871537
Autor:
Hanbo Pan, Yu Tian, Hui Wang, Long Jiang, Zenan Gu, Hongda Zhu, Junwei Ning, Jia Huang, Qingquan Luo
Publikováno v:
Cancers; Volume 14; Issue 21; Pages: 5249
(1) Background: Despite the fact that robotic-assisted thoracoscopic lobectomy (RATL) has been prevalently applied for early stage non-small cell lung cancer (NSCLC), its superiorities are still to be fully revealed for patients with metastatic N1 ly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4e5897688661d375fdc51b48ca3f822
https://doi.org/10.3390/cancers14215249
https://doi.org/10.3390/cancers14215249